Brolucizumab

Brolucizumab
Monoclonal antibody
Type Single-chain variable fragment
Source Humanized
Target VEGFA
Clinical data
Synonyms ESBA1008, RTH258
Routes of
administration		 intravitreal
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Formula C1164H1768N310O372S7
Molar mass 26.31 kDa

Brolucizumab (INN) is a humanized monoclonal antibody designed for the treatment of wet age-related macular degeneration.[1][2]

This drug was developed by ESBATech and Alcon Laboratories, Inc.

Laboratory development names are RTH258 (Novartis Compound Code) and ESBA1008 (ESBATech AG).

It is currently at Phase III trials.

References

  1. ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Brolucizumab, American Medical Association.
  2. ↑ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 112" (PDF). WHO Drug Information. 28 (4).
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.